30-Day Insulin Balance and Metabolic Health Program
30 Day Insulin Balance Metabolic Health Optimization Protocol
This 30-day program will see if taking the Insulin Balance dietary supplement helps generally healthy adults maintain healthy insulin levels and reduce weight, fatigue, and sugar cravings.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Efforia, Inc Industry-sponsored |
| Locations | 1 site (New York, New York) |
| Trial ID | NCT07478497 on ClinicalTrials.gov |
What this trial studies
This single-arm, 30-day Signal Phase program asks generally healthy adults to take the Insulin Balance Formula daily and serve as their own controls. Participants begin with one capsule to assess tolerance and progress to three capsules daily (ideally one before each meal) while completing body composition measures and questionnaires on sleep disturbance, carbohydrate cravings, and after-meal hunger and fatigue. The protocol is observational and designed to detect early signs of metabolic and weight-related benefit while collecting initial safety data. Findings will be used to inform whether larger, controlled trials are warranted.
Who should consider this trial
Good fit: Adults age 18 and older who are generally healthy, can read English, give informed consent, and can follow daily supplement and questionnaire procedures are ideal candidates.
Not a fit: People with diagnosed insulin disorders, GI, sleep, or mental health disorders, pregnant or nursing individuals, those on medications, people with known allergies to the product, competitive athletes under specific regulations, and those sensitive to fatigue are excluded and unlikely to benefit from this protocol.
Why it matters
Potential benefit: If successful, the supplement could help adults maintain healthier insulin levels and modestly improve weight, energy, and sugar cravings.
How similar studies have performed: Previous small trials of dietary supplements targeting insulin and metabolic symptoms have produced mixed, limited results, and well-controlled evidence is lacking.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults 18+ who are generally healthy * Ability to read and comprehend English * Ability to willfully consent and follow study procedures and tasks Exclusion Criteria: * Individuals with Known Allergies * Pregnant or Nursing Individuals * Individuals with Insulin Disorders * Individuals with GI Disorders * Individuals with Mental Health Conditions * Individuals with Sleep Disorders * Individuals on Medication * Athletes under Specific Regulations * Individuals Sensitive to Fatigue
Where this trial is running
New York, New York
- Efforia — New York, New York, United States (Recruiting)
Study contacts
- Study coordinator: Matthew Amsden
- Email: help@efforia.com
- Phone: (646) 679-2479
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.